The harmful use of alcohol has been estimated to cause approximately 3.3 million deaths
every year, corresponding to nearly 6% of all deaths globally. Therefore, the effective …

Histological fibrosis stage is one of the most important prognostic factors in compensated
and decompensated alcohol-related liver disease (ALD). Morphological assessment of …

Alcoholic liver disease (ALD) is the most prevalent type of chronic liver disease worldwide.
ALD can progress from alcoholic fatty liver (AFL) to alcoholic steatohepatitis (ASH), which is …

Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes,
but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We …

Background & Aims Few data exist on predictors of long-term prognosis in patients with
alcoholic liver disease (ALD). Most studies have only assessed short-term prognosis in …

Non-alcoholic fatty liver disease (NAFLD) encompasses the simple steatosis to more
progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases …

Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are significant
causes of chronic liver disease worldwide. Both are characterized by histological lesions …

Nonalcoholic fatty liver disease (NAFLD) is recognized as the leading cause of chronic liver
disease in adults and children. NAFLD encompasses a spectrum of liver injuries ranging …

Nonalcoholic fatty liver disease (NAFLD), defined as abnormal accumulation (> 5%) of
hepatic triglyceride without excess alcohol intake, is the most common form of chronic liver …

Nonalcoholic fatty liver disease (NAFLD) results in histologically complex specific and
nonspecific injury patterns. In clinical research of NAFLD, the liver biopsy evaluation …